On July 29, 2026, the FDA granted De Novo approval to the CaRi-Heart system (software that uses artificial intelligence to analyze routine CT angiography of coronary arteries). CaRi-Heart can detect inflammatory risks that are not visible in the standard assessment of stenosis and plaques. (translated)

